DAXXIFY Becomes First Facial Injectable to be Named to TIME’s Best Inventions

TIME has unveiled its annual Best Inventions list, which features 200 of the year’s best innovations that are making the world better, smarter, and more enjoyable.

For 2023, TIME solicited nominations from their editors and correspondents around the world, and through an application process, paying special attention to growing fields – such as AI, green energy, and sustainability. The entrants were then evaluated against a number of key factors, including originality, efficacy, ambition, and impact.

Of the new list, TIME’s editors write: “The result is a list of 200 groundbreaking inventions (and 50 special mention inventions) — including the world's most powerful supercomputer, a game-changing entertainment venue, and a new shape — that are changing how we live, work, play, and think about what’s possible.”

DAXXIFY - The First True Innovation in Neuromodulator Formulation in More Than 30 Years

DAXXIFY, the first and only peptide-formulated, long-lasting neuromodulator, was named as one of TIME’s 2023 Best Inventions. Unlike conventional neuromodulators, DAXXIFY is the only neuromodulator product manufactured exclusively in the U.S. and was developed to address duration of treatment effect, as nearly 90% of patients and physicians desire a treatment that lasts longer.¹

As the first facial injectable to be selected for this award, DAXXIFY’s differentiation is clear. With an innovative formulation and strong performance profile, DAXXIFY, which is FDA approved for the temporary improvement of moderate to severe frown lines (glabellar lines) in adults, is disrupting the $2.5B U.S. aesthetics neuromodulator market and establishing a new category of long-acting, peptide-enhanced neuromodulators, creating value for providers and patients.²

“We are honored to be recognized by TIME and are encouraged by the expanding impact of DAXXIFY in the aesthetics space. By leveraging research in the emerging field of peptide technology and after evaluating a number of peptide sequences, Revance developed an injectable formulation that doesn’t require animal or human components to stabilize the toxin like competitor products. DAXXIFY has demonstrated the ability to deliver high patient satisfaction stemming from long-lasting results, fast onset and the appearance of improved skin texture*, providing the first true innovation in neuromodulator product formulation in over 30 years,” said Mark Foley, Chief Executive Officer. “The aesthetic facial injectables market is robust and growing and we are very pleased to be setting the new standard with DAXXIFY.”